You don't hear much talk of it on AAS boards, even though it's supposed to be superior to nolva for gyno protection. I was wondering why more gyno prone people don't run it
You don't hear much talk of it on AAS boards, even though it's supposed to be superior to nolva for gyno protection. I was wondering why more gyno prone people don't run it
It was really designed to be marketed to post-menopausal women from my observation, with an estrogen sub-receptor profile to reflect that demographic. It's quite possibly a good preemptive, but once gyno appears even massive amounts are generally useless. The bioavailability sux too (only about 2% of an oral dose actually get's to the bloodstream in tact.)
So cost and availability may be big factors why it's not more popular, but it basically isn't that good to begin with.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.